, tackling inequities in access and quality of care for patients with multiple myeloma, and preventing and managing blood clots. Speakers also shared information and research pertaining to the treatment of adult acute lymphoblastic leukemia, acute myeloid
Search Results
The NCCN 2023 Annual Congress: Hematologic Malignancies
Crystal S. Denlinger
JNCCN CE Offerings
-Acquired Resistance in the Brain and Histologic Transformation in the Lung Expiration Date: 9/19/14 NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 2.2013 Expiration Date: 9/19/14 Controversies in the Treatment of Elderly Patients With Newly
How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?
Sanam Loghavi, Mark J. Routbort, Keyur P. Patel, Rajyalakshmi Luthra, Wei-Lien Wang, Russell R. Broaddus, Michael A. Davies, and Alexander J. Lazar
neoplasms. 13 – 34 We now have strong evidence to support molecular testing in patients with various types of cancer, including lung carcinoma, melanoma, colorectal carcinoma, and acute myeloid leukemia, as part of routine clinical practice and standard of
NCCN News
cancers and acute myeloid leukemia. The report grew out of the discussion held by the group in May 2011, when NCCN assembled the task force, comprising oncologists and pathologists from the NCCN Member Institutions and expert participants from the NCI and
New Agents in Chronic Myelogenous Leukemia
Jorge Cortes and Francis Giles
elevated in myelodysplastic syndromes and in acute myeloid leukemia . J Hematother Stem Cell Res. 2002 ; 11 : 119 – 125 . 69 Aguayo A Kantarjian H Manshouri T . Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
Treatment of Acute Promyelocytic Leukemia for Older Patients
Thomas Prebet and Steven D. Gore
T he treatment of acute myeloid leukemia (AML) in older patients remains challenging. 1 Both disease- and patient-related factors unfavorably influence patient outcome, with a 2-year probability of overall survival of 10% to 15%. 2 Acute
Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010
Mikkael A. Sekeres
focused on the evolution of lower- and higher-risk MDS into more aggressive forms of either MDS or acute myeloid leukemia (AML), and has necessitated a clearer description of how these drugs are being used across the country. MDS Epidemiology
Prevention, Diagnosis, and Treatment of Invasive Fungal Infections in Patients with Cancer and Neutropenia
Thomas A. Cumbo and Brahm H. Segal
1 Bow EJ Loewen R Cheang MS . Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults . J Clin Oncol 1997 ; 15 : 2254 – 2261 . 2 Pfaller MA
Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report
Eugene R. Przespolewski, Jeffrey Baron, Farshid Kashef, Kai Fu, Sheila N. Jani Sait, Francisco Hernandez-Ilizaliturri, and James Thompson
many types of cancer, including CLL, acute myeloid leukemia, and CML. 4 , 19 – 27 Venetoclax is now an established therapeutic option in CLL, for use as first-line therapy or in relapsed/refractory disease. 3 , 4 , 28 – 30 This report presents a case
Synergistic Interactions of Molecular and Clinical Advances for Characterizing the Myelodysplastic Syndromes
Peter L. Greenberg
aggressive (acute myeloid leukemia [AML]). Clinical and biological complexity has become apparent in this spectrum of disorders. To help to more clearly define the clinical status, prognosis, and therapeutic strategies for these patients, several clinical